Ultragenyx Pharmaceutical Inc. Common Stock (RARE)
Stock · NASDAQ · Health Care
$14.55as of 10/16/2026
Price chart
Active signals
RARE Signal Track Record
How signals performed across all stocks →What RARE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -0.2% | 50% | September 17, 2026 |
| Bollinger Band Breakout | 25 | -1.5% | 48% | June 30, 2026 |
| Bollinger Band Breakdown | 23 | +0.3% | 57% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -4.4% | 35% | August 25, 2026 |
| Any 20-session window (baseline) | -2.1% | 43% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatm…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,371
- Website
- www.ultragenyx.com/
Fundamentals
- 1-day range
- $14.44$15.21
- Market cap
- $2.54B
- P/E (trailing)
- —
- P/E (forward)
- 64.45
- EPS (trailing)
- $-5.84
- Dividend yield
- —
- Beta
- 0.35
- Avg. volume
- 4.03M
How Ultragenyx Pharmaceutical Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
20 analyst ratings
Ultragenyx Pharmaceutical Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
- PGENPrecigen Inc. Common Stock$6.39▼ 11.25%Market cap $2.47BP/E —$3.04$8.98
- NRIXNurix Therapeutics Inc. Common stock$24.42▼ 2.12%Market cap $2.62BP/E 9.25$9.14$28.23
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
- KLRAKailera Therapeutics Inc. Common Stock$11.25▼ 3.93%Market cap $2.44BP/E —$9.76$28.23
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
| PGEN Precigen Inc. Common Stock | $2.47B | — | $6.39 | ▼ 11.25% | $3.04$8.98 |
| NRIX Nurix Therapeutics Inc. Common stock | $2.62B | 9.25 | $24.42 | ▼ 2.12% | $9.14$28.23 |
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
| KLRA Kailera Therapeutics Inc. Common Stock | $2.44B | — | $11.25 | ▼ 3.93% | $9.76$28.23 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16benzinga · 10/15/2026
- FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsYahoo · 10/9/2026
- Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost CashYahoo · 10/8/2026
- Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?Yahoo · 10/8/2026
- Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 millionYahoo · 10/7/2026
- Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying OpportunityYahoo · 10/7/2026
- Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 MillionYahoo · 10/7/2026
- MARKETS LIVE: US futures slide ahead of Fed minutes as bond yields and oil riseYahoo · 10/7/2026
- Ultragenyx Pharmaceutical Inks $210M Deal To Sell Rare Pediatric Disease Priority Review VoucherBenzinga · 10/7/2026
Insider Activity
Insider Actions →- Theodore Alan Huizenga · September 15, 2026 · Sale1.3K @ $13.57
- Theodore Alan Huizenga · September 3, 2026 · Sale161 @ $13.99
- Karah Herdman Parschauer · August 3, 2026 · Sale1.9K @ $24.92
- Howard Horn · August 3, 2026 · Sale4.7K @ $24.92
- Howard Horn · July 1, 2026 · Sale4.7K @ $33.13
- Karah Herdman Parschauer · June 15, 2026 · Sale1.9K @ $24.62
- Corazon (Corsee) D. Sanders · June 15, 2026 · Sale2.0K @ $25.05
- Howard Horn · June 1, 2026 · Sale4.7K @ $23.77
- Shehnaaz Suliman · May 18, 2026 · Sale5.7K @ $25.12
- Amrit Ray · May 14, 2026 · Grant14.1K
- Amrit Ray · May 14, 2026 · Grant7.8K
- Corazon (Corsee) D. Sanders · May 14, 2026 · Grant14.1K
- Corazon (Corsee) D. Sanders · May 14, 2026 · Grant7.8K
- Shehnaaz Suliman · May 14, 2026 · Grant14.1K
- Shehnaaz Suliman · May 14, 2026 · Grant7.8K
Institutional Ownership
March 31, 2026
- Total shares held
- 93.77M
- Total value held
- $1.87B
- Institutional holders
- 286
- Unknown7.30M
- Unknown5.02M
- Unknown4.58M
- Unknown4.19M
- Unknown3.65M
- Unknown3.50M
- Unknown3.21M
- Unknown2.64M
- Unknown2.38M
- Unknown2.37M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RARE FDA approves Fayuvi, triggers $203M voucher sale
Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.
RARE FDA approves Fayuvi, triggers $203M voucher sale. Ultragenyx Pharmaceutical received FDA approval for its gene therapy Fayuvi. The approval was followed by a second sale of a priority review voucher, bringing in about $203 million within a week. The cash from the voucher sale adds to the company’s resources as it looks to expand its approved product portfolio. Analysts are evaluating whether the newly approved product can support the next growth phase.